Basis for molecular diagnostics and immunotherapy for esophageal cancer-Reference-Cited by-同舟云学术

Basis for molecular diagnostics and immunotherapy for esophageal cancer

Published:2016-11-23 Issue:1 Volume:17 Page:33-45
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Abdo Joe¹,Agrawal Devendra K.¹,Mittal Sumeet K.¹²

Affiliation:

1. Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, USA

2. Department of Surgery, Creighton University School of Medicine (Phoenix campus), Norton Thoracic Institute, Dignity Health, Phoenix, AZ, USA

Funder

National Heart, Lung and Blood Institute, National Institutes of Health, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2017.1260449

Reference79 articles.

1. Segments of Molecular Diagnostics – Market Place

2. Hughes MD. Molecular diagnostics market trends and outlook [webpage on the Internet] Enterprise Analysis Corporation. 2014. Available from: http://www.eacorp.com/images/PDFS/Molecular%20Diagnostics%20IVD%20Article%20v21%20MEK%20-%20Reprint%20FINAL.pdf.

3. Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma

4. Barrett's esophagus: recent insights into pathogenesis and cellular ontogeny

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of triboelectric nanogenerator (TENG) in cancer prevention and adjuvant therapy;Colloids and Surfaces B: Biointerfaces;2024-10

2. Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy;Biomedicine & Pharmacotherapy;2024-08

3. An updated review of immunotherapy in esophageal cancer: PD-L1 footprint;Central European Journal of Immunology;2024

4. miR-140-3P Induces Chemotherapy Resistance in Esophageal Carcinoma by Targeting the NFYA-MDR1 Axis;Applied Biochemistry and Biotechnology;2022-10-18

5. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer;Frontiers in Immunology;2022-09-28